Skip to main content

Table 4 Cost and cost-effectiveness of universal GA-I newborn screening at differing prevalence rates and low versus high incremental screening cost

From: Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis

  Incremental screening cost 0.03 Euro/neonate Incremental screening cost 0.3 Euro/neonate
Prevalence Mean incremental cost per 100000 screened neonates (95% CI) ICER Mean incremental cost per 100000 screened neonates (95% CI) ICER (95% CI)
1 in 35,000 −103,445 (−160,339 – -52,919) <0 −76,545 (−133,439 – -26,019) <0
1 in 100,000 −34,191 (−54,104 – -16,507) <0 −7,291 (−27,204 – 10,393) −1,750 (−6,417 - 2,657)
1 in 200,000 −15,545 (−25,502 – -6,703) <0 11,355 (1,398 – 20,197) 5,703 (651 – 10,728)
1 in 350,000 −7,555 (− 13,244 – - 2,502) <0 19,345 (13,656 – 24,398) 16,882 (10,800 – 23,491)
  1. All values in Euro, 20 years horizon.